Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-DM: Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
NCT05942963Phase 4Unknown
- Sponsor
- Jinnah Postgraduate Medical Centre
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin, pioglitazone in non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), sponsored by Jinnah Postgraduate Medical Centre. Status: unknown.
02
Drugs
empagliflozinpioglitazone
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05942963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942963.